Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edwards Lifesciences CorpEW · Entity 3026 | SVP, Corporate Controller | May 11, 2024 | May 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edwards Lifesciences Corp
Report date May 11, 2024 · Filed May 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 17,081.198 |
Reported balance
After 2024-05-11 transaction · row 1
1 source rowRow 1 · 2024-05-11 · Tax withholding · Disposed 229 · Balance 17,081.198 |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 20,409 |
Reported balance
Holding disclosure · report date 2024-05-11 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 20,409 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 11, 2024 Filed May 13, 2024 21:47 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 229 | $86.72 | $19,858.88 |
DisclosureSEC source: 0001225208-24-005986 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,081.198 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 4,820 | $0.00 Strike: $85.84 | $0.00 |
DisclosureSEC source: 0001225208-24-005884 · doc4.xml · derivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,820 Underlying: Common Stock · 4,820 shares Expires 2031-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 178 | $85.09 | $15,146.02 |
DisclosureSEC source: 0001225208-24-005884 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,310.198 Read SEC document |
| May 07, 2024 Filed May 9, 2024 23:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 2,445 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-005884 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,488.198 F1 · shares: These restricted stock units were granted on May 7, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 120 | $85.25 | $10,230.00 |
DisclosureSEC source: 0001225208-24-005705 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,043.198 Read SEC document |
| May 03, 2024 Filed May 6, 2024 23:18 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 106 | $85.06 | $9,016.36 |
DisclosureSEC source: 0001225208-24-005705 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,163.198 Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 23:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,998 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-24-002857 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,085.1838 F1 · shares: These restricted stock units were granted on February 22, 2024 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 22:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 12,210 | $0.00 Strike: $36.75 | $0.00 |
DisclosureSEC source: 0001225208-24-001867 · doc4.xml · derivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,210 shares Expires 2024-05-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 22:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,210 | $87.00 | $1,062,270.00 |
DisclosureSEC source: 0001225208-24-001867 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,087.1838 Read SEC document |
| February 12, 2024 Filed Feb 12, 2024 22:44 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 12,210 | $36.75 | $448,717.50 |
DisclosureSEC source: 0001225208-24-001867 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,297.1838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 5,540 | $0.00 Strike: $88.78 | $0.00 |
DisclosureSEC source: 0001225208-23-005920 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,540 Underlying: Common Stock · 5,540 shares Expires 2030-05-10 F2 · derivative.exercise_date: These options were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 11, 2023 Filed May 15, 2023 22:28 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-23-005920 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,035.7904 F1 · shares: These restricted stock units were granted on May 11, 2023 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 08, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 161 | $88.74 | $14,287.14 |
DisclosureSEC source: 0001225208-23-005621 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,235.7904 Read SEC document |
| May 07, 2023 Filed May 9, 2023 23:50 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 134 | $88.74 | $11,891.16 |
DisclosureSEC source: 0001225208-23-005621 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,396.7904 Read SEC document |
| May 04, 2023 Filed May 5, 2023 01:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 116 | $88.10 | $10,219.60 |
DisclosureSEC source: 0001225208-23-005432 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,530.7904 Read SEC document |
| May 03, 2023 Filed May 5, 2023 01:48 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 103 | $87.81 | $9,044.43 |
DisclosureSEC source: 0001225208-23-005432 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,646.7904 Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 12,270 | $0.00 Strike: $35.20 | $0.00 |
DisclosureSEC source: 0001225208-23-005181 · doc4.xml · derivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,270 shares Expires 2023-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,270 | $87.20 | $1,069,944.00 |
DisclosureSEC source: 0001225208-23-005181 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,749.7904 Read SEC document |
| April 28, 2023 Filed Apr 28, 2023 23:08 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 12,270 | $35.20 | $431,863.51 |
DisclosureSEC source: 0001225208-23-005181 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,019.7904 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2022 Filed May 18, 2022 01:16 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 211 | $95.93 | $20,241.23 |
DisclosureSEC source: 0001225208-22-007137 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,436.4609 Read SEC document |
| May 08, 2022 Filed May 11, 2022 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 155 | $100.52 | $15,580.60 |
DisclosureSEC source: 0001225208-22-006810 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,647.4609 Read SEC document |
| May 07, 2022 Filed May 11, 2022 00:52 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 134 | $100.52 | $13,469.68 |
DisclosureSEC source: 0001225208-22-006810 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,802.4609 Read SEC document |
| May 04, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 116 | $105.93 | $12,287.88 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,936.4609 Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 3,480 | $0.00 Strike: $105.93 | $0.00 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · derivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,480 Underlying: Common Stock · 3,480 shares Expires 2029-05-02 F2 · derivative.exercise_date: These options were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,180 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-22-006583 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · SVP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,052.4609 F1 · shares: These restricted stock units were granted on May 3, 2022 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:31 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 204 | $89.49 | $18,255.96 |
DisclosureSEC source: 0001225208-21-008304 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,555.6925 Read SEC document |
| May 11, 2021 Filed May 13, 2021 01:38 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 274 | $90.40 | $24,769.60 |
DisclosureSEC source: 0001225208-21-008060 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,759.6925 Read SEC document |
| May 07, 2021 Filed May 11, 2021 21:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 133 | $91.75 | $12,202.75 |
DisclosureSEC source: 0001225208-21-007971 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,033.6925 Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 4,250 | $0.00 Strike: $93.31 | $0.00 |
DisclosureSEC source: 0001225208-21-007712 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 4,250 shares Expires 2028-05-03 F2 · derivative.exercise_date: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 04, 2021 Filed May 7, 2021 01:12 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 1,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-007712 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,166.6925 F1 · shares: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| April 23, 2021 Filed Apr 24, 2021 01:26 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 12,000 | $97.66 | $1,171,976.40 |
DisclosureSEC source: 0001225208-21-006982 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 20,409 F1 · price: This transaction was executed in multiple trades at prices ranging from $97.6600 to $97.6800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 10, 2020 Filed Feb 13, 2021 01:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 32,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002471 · doc5.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 32,409 Read SEC document |
| December 10, 2020 Filed Feb 13, 2021 01:39 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GiftCommon Stock | 32,409 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-21-002471 · doc5.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,642.1372 Read SEC document |
| August 27, 2020 Filed Aug 27, 2020 22:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 21,540 | $0.00 Strike: $21.76 | $0.00 |
DisclosureSEC source: 0001225208-20-011069 · doc4.xml · derivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,540 shares Expires 2022-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 27, 2020 Filed Aug 27, 2020 22:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 21,540 | $82.60 | $1,779,160.92 |
DisclosureSEC source: 0001225208-20-011069 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,040.1239 F1 · price: This transaction was executed in multiple trades at prices ranging from $82.5300 to $82.7900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 27, 2020 Filed Aug 27, 2020 22:14 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 21,540 | $21.76 | $468,710.40 |
DisclosureSEC source: 0001225208-20-011069 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,580.1239 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 12, 2020 Filed May 13, 2020 20:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 88 | $225.05 | $19,804.40 |
DisclosureSEC source: 0001225208-20-007575 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,941.7761 Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:15 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 88 | $217.84 | $19,169.92 |
DisclosureSEC source: 0001225208-20-007575 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,029.7761 Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantEmployee Stock Option (Right to Acquire) · Derivative | 1,700 | $0.00 Strike: $218.04 | $0.00 |
DisclosureSEC source: 0001225208-20-007344 · doc4.xml · derivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,700 Underlying: Common Stock · 1,700 shares Expires 2027-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2020 Filed May 9, 2020 01:51 UTC | Edwards Lifesciences Corp EW · Entity 3026 | GrantCommon Stock | 515 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-007344 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,117.7761 F1 · shares: These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 7,297 | $211.57 Strike: $35.79 | $1,543,837.24 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · derivative · entry 8 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,297 shares Expires 2020-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionEmployee Stock Option (Right to Acquire) · Derivative | 10,120 | $211.57 Strike: $41.94 | $2,141,103.58 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · derivative · entry 7 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,120 shares Expires 2021-05-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,992 | $211.41 | $1,055,357.22 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 6 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,535.2377 F4 · price: This transaction was executed in multiple trades at prices ranging from $210.8000 to $211.7800. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,800 | $212.30 | $1,019,037.12 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 5 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,527.2377 F3 · price: This transaction was executed in multiple trades at prices ranging from $211.8100 to $212.5500. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 4,625 | $209.99 | $971,184.33 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 4 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,327.2377 F2 · price: This transaction was executed in multiple trades at prices ranging from $209.7850 to $210.1900. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | SaleCommon Stock | 3,000 | $213.12 | $639,362.40 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 3 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,952.2377 F1 · price: This transaction was executed in multiple trades at prices ranging from $213.0300 to $213.3300. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 7,297 | $35.79 | $261,123.15 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,952.2377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2019 Filed Jul 27, 2019 00:03 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Exercise / conversionCommon Stock | 10,120 | $41.94 | $424,432.80 |
DisclosureSEC source: 0001225208-19-010542 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,655.2377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 14, 2019 Filed May 14, 2019 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 143 | $178.17 | $25,478.31 |
DisclosureSEC source: 0001225208-19-007995 · doc4.xml · nonDerivative · entry 2 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,446.9846 Read SEC document |
| May 12, 2019 Filed May 14, 2019 23:04 UTC | Edwards Lifesciences Corp EW · Entity 3026 | Tax withholdingCommon Stock | 85 | $181.10 | $15,393.50 |
DisclosureSEC source: 0001225208-19-007995 · doc4.xml · nonDerivative · entry 1 SELLERS ROBERT W.A. · CIK 0001600739 · VP, Corporate Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,589.9846 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.